Doximity (NYSE:DOCS) Stock Gets Price Target Boost from Canaccord Genuity Group

Doximity (NYSE:DOCS) had its price target lifted by analysts at Canaccord Genuity Group from $36.00 to $40.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group‘s price target indicates a potential upside of 24.36% from the company’s current price.

Other research analysts have also issued reports about the company. Needham & Company LLC reissued a “buy” rating and set a $41.00 price target on shares of Doximity in a report on Friday. Piper Sandler reaffirmed an “overweight” rating and issued a $47.00 price objective (up from $42.00) on shares of Doximity in a report on Friday, August 7th. Zacks Research upgraded shares of Doximity from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Royal Bank Of Canada raised their target price on shares of Doximity from $28.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Evercore set a $35.00 price target on shares of Doximity in a research report on Tuesday, September 29th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $30.45.

Doximity Stock Down 3.1%

NYSE DOCS traded down $1.02 during trading hours on Friday, hitting $32.16. The company had a trading volume of 2,769,843 shares, compared to its average volume of 3,882,713. The business has a fifty day simple moving average of $28.95 and a 200-day simple moving average of $25.55. The firm has a market cap of $5.73 billion, a P/E ratio of 37.98, a price-to-earnings-growth ratio of 27.12 and a beta of 1.29. Doximity has a fifty-two week low of $17.15 and a fifty-two week high of $58.24.

Doximity (NYSE:DOCS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.13. Doximity had a return on equity of 18.06% and a net margin of 25.48%. The company had revenue of $156.62 million during the quarter. During the same quarter last year, the firm posted $0.36 EPS. The company’s revenue was up 7.3% compared to the same quarter last year. Equities analysts forecast that Doximity will post 0.74 EPS for the current fiscal year.

Insider Transactions at Doximity

In other news, Director Kira Wampler sold 2,000 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $32.89, for a total value of $65,780.00. Following the sale, the director owned 27,923 shares of the company’s stock, valued at approximately $918,387.47. The trade was a 6.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Siddharth Sitaram sold 2,613 shares of the company’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total value of $80,166.84. Following the completion of the sale, the chief accounting officer owned 101,432 shares of the company’s stock, valued at approximately $3,111,933.76. This trade represents a 2.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 13,750 shares of company stock valued at $386,310. Corporate insiders own 31.80% of the company’s stock.

Institutional Investors Weigh In On Doximity

Institutional investors and hedge funds have recently bought and sold shares of the business. Carmignac Gestion grew its stake in shares of Doximity by 127.8% in the 1st quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock worth $100,480,000 after purchasing an additional 2,418,971 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Doximity by 24.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock worth $65,022,000 after purchasing an additional 621,464 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Doximity by 29.4% during the first quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock valued at $71,292,000 after purchasing an additional 694,300 shares during the last quarter. Bank of America Corp DE lifted its stake in Doximity by 31.8% during the first quarter. Bank of America Corp DE now owns 1,142,530 shares of the company’s stock valued at $26,621,000 after purchasing an additional 275,650 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Doximity by 0.4% during the first quarter. Bank of New York Mellon Corp now owns 1,040,534 shares of the company’s stock valued at $24,244,000 after purchasing an additional 4,271 shares during the last quarter. 87.19% of the stock is owned by institutional investors and hedge funds.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported fiscal Q2 2027 revenue of $174.5 million and earnings of $0.36 per share, beating estimates. It also forecast Q3 revenue of $195–$196 million and fiscal 2027 revenue of $678–$683 million, both above consensus. Management cited record engagement, a 51% adjusted EBITDA margin, and more than 190 health systems purchasing its AI suite. Fiscal 2027 Q2 results
• Positive Sentiment: Needham reaffirmed its Buy rating and $41 price target, signaling potential upside from the current share price. Needham analyst rating
• Negative Sentiment: The stock’s weak response contrasts with the earnings beat. Quarterly revenue grew 3.6% year over year, while EPS declined from $0.45 a year earlier to $0.36—potentially raising concerns about the pace of growth and earnings trends. Doximity quarterly results and stock reaction
• Negative Sentiment: Several law firms highlighted a securities class action and the November 16 lead-plaintiff deadline. The complaint alleges that Doximity misrepresented the contribution of its Newsfeed advertising product to growth; these claims have not been proven, but the litigation may add investor uncertainty. Class action deadline notice
• Neutral Sentiment: A director sold 2,000 shares under a pre-arranged Rule 10b5-1 plan. The transaction was relatively small and scheduled in advance, so it may have limited significance on its own. Director share sale

About Doximity

Doximity, Inc operates a digital platform designed for medical professionals in the United States. Its network connects physicians, nurse practitioners, physician assistants, pharmacists and other healthcare professionals, providing tools for professional communication, collaboration and career development.

The company offers services including secure messaging, telehealth, digital faxing, physician scheduling and professional networking. Doximity also provides medical news and educational content, as well as recruiting and job-search resources for healthcare professionals.

Doximity generates additional revenue through digital marketing and engagement solutions for pharmaceutical companies, healthcare organizations and health systems.